ClinicalTrials.gg
RecruitingNCT04694924ProsquareUpdated May 22, 2024

Prospective Prostate Cancer and Patient-reported Outcomes Registry

An observational study in Prostate Cancer, Adenocarcinoma of the Prostate and Locally Advanced Prostate Carcinoma, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 4 sites in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-22.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Observational

How we know

From the registry’s dates

  • Started Oct 2020; still recruiting 6 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
5,000
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven — 8 open to participants now, 11 under way, 3 of them phase 3. Prostatic Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Started
2020
with 2 others
Observational
2 of 12
2 open now
Primary completion
2030-10
later than 10 of 10 live
Registered
9th of 12
by date

Among the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is one of 3 that started in 2020, is one of 2 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 9th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.

03

Conditions studied

  • Prostate Cancer
  • Adenocarcinoma of the Prostate
  • Locally Advanced Prostate Carcinoma
  • Locally Advanced Prostate Adenocarcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with newly diagnosed histologically proven localized and locally advanced prostate cancer referred to one of the participating sites will be eligible to be enrolled in the cohort.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pathology confirmed diagnosis of localized or locally advanced prostate cancer
  • Being able to speak, read and understand Dutch, French, or English
  • Each patient (or their legally acceptable representative) must sign an form (ICF) indicating that he understands the purpose of, and is willing to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients with prior treatment for prostate will be excluded.
  • Dementia, mental alteration, or psychiatric pathology that can compromise from the patient and/ or adherence to the protocol and the monitoring of the trial
  • Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical.
  • Persons deprived of liberty or under guardianship
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
5,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • Localized and locally advanced prostate cancer

    Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.

    Other: standard of care

Interventions

  • Otherstandard of care

    No other procedures than those performed during the usual care for prostate cancer patients will be done. No study medication will be provided as part of participation. Clinical outcomes will be reported via predefined electronic forms, integrated into the electronic health record (EHR). Patient-reported outcomes will be collected electronically. All treatment decisions will be made at the discretion of the investigator or treating physician.

06

What researchers measure

Primary outcomes

  1. Assessment of systematically reporting a standardized set of predefined clinical parameters

    The proportion of patients who are enrolled in the registry over the total localized and locally advanced prostate cancer patients

    Time frame: up to 10 years after diagnosis

  2. Assessment of systematically collecting a predefined set of patient-reported outcomes

    The proportion of patients who completed all questionnaires over the total of questionnaires send.

    Time frame: up to 10 years after diagnosis

Secondary outcomes

  1. Occurence of disease recurrence/progression

    Biochemical prostate specific antigen (PSA) recurrence/progression and recurrence/progression based on medical imaging

    Time frame: up to 10 years after diagnosis

  2. General quality of life

    Assessment of health-related quality of life in prostate cancer patients. Measured by EORTC Quality of Life Questionnaire C30 (QLQ-C30). The EORTC QLQ-C30 is a generic QoL questionnaire designed to cover issues important to all cancer patients

    Time frame: at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis

  3. Prostate cancer specific quality of life

    Measured by Extended Prostate cancer Index Composite 26 (EPIC26). EPIC-26 is a validated instrument that measures the quality of life across 5 disease-specific domains: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms.

    Time frame: at diagnosis, 6 months, 1 year, and annually up to 10 years after diagnosis

  4. Overall Survival (OS)

    Overall survival is defined as the time from enrollment to date of death due to any cause.

    Time frame: up to 10 years after diagnosis

  5. Prostate Cancer (PC)-related Mortality (PM)

    PC-related mortality is the death due to prostate cancer.

    Time frame: up to 10 years after diagnosis

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Oct 2030, 120 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 120 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2020
First posted
Jan 5, 2021
StartActual
Oct 1, 2020
Primary completionEst.
Oct 2030
CompletionEst.
Oct 2030
Last update
May 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04694924
Collaborators
AZ Sint-Jan AV, General Hospital Groeninge, AZ Sint-Blasius Dendermonde
Responsible party
Sponsor
First posted
Jan 5, 2021
Start date
Oct 1, 2020
Primary completion
Oct 2030 (estimated)
Completion
Oct 2030 (estimated)
Last update
May 22, 2024

Study contacts

Wouter Everaerts, MD, PhD
Contact
wouter.everaerts@uzleuven.be
+3216346687
Wouter Everaerts, MD, PhD
principal investigator · UZ Leuven / KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion